Trial reportLancet (London, England)2006
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
Trial report in Lancet (London, England), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00029848 (A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety in Obese Patients With Type 2 Diabetes), which is not on this map. Cited by 187 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety in Obese Patients With Type 2 Diabetes
Who cites it
187 citing papers in PubMed, 7 syntheses or guidelines pooled it, 735 citations in OpenAlex.
- Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review.Diabetologia · 2024Pooled it
- Effect of cannabis and subproducts on anthropometric measures: a systematic review and meta-analysis.International journal of obesity (2005) · 2024Pooled it
- Long-term effects of weight-reducing drugs in people with hypertension.The Cochrane database of systematic reviews · 2021Pooled it
- Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis.International journal of obesity (2005) · 2011Pooled it
- Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.BMC gastroenterology · 2009Pooled it
- Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2009Pooled it
- Long-term pharmacotherapy for obesity and overweight.The Cochrane database of systematic reviews · 2004Pooled it
- Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.BMC endocrine disorders · 2017Trial
- The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.The international journal of neuropsychopharmacology · 2015Trial
- Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.The international journal of neuropsychopharmacology · 2014Trial
- Trial
- Does rimonabant independently affect free fatty acid and glucose metabolism?The Journal of clinical endocrinology and metabolism · 2012Trial
- The development and description of the comparison group in the Look AHEAD trial.Clinical trials (London, England) · 2011Trial
- Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial.Diabetes care · 2010Trial
- Trial
- Peripheral endocannabinoid system activity in patients treated with sibutramine.Obesity (Silver Spring, Md.) · 2008Trial
- Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.Current atherosclerosis reports · 2007Trial
- Discrete Choice Experiment (DCE) as a Tool to Elicit Patient Preferences in a Complex Benefit-Risk Evaluation: A Case Study.Clinical drug investigation · 2026Article
- Methodological comparisons for benefit-risk assessment in complex decision-making: applications and insights from a case study.Frontiers in drug safety and regulation · 2026Article
- Endocannabinoid and AGE Interactions in Prediabetes: The Role of Mediterranean Diet Adherence.Nutrients · 2025Article
127 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin or sulphonylureas.
methods1047 overweight or obese type 2 diabetes patients (body-mass index 27-40 kg/m2) with a haemoglobin A1c (HbA1c) concentration of 6.5-10.0% (mean 7.3% [SD 0.9] at baseline) already on metformin or sulphonylurea monotherapy were given a mild hypocaloric diet and advice for increased physical activity, and randomly assigned placebo (n=348), 5 mg/day rimonabant (360) or 20 mg/day rimonabant (339) for 1 year. Two individuals in the 5 mg/day group did not receive double-blind treatment and were thus not included in the final analysis. The primary endpoint was weight change from baseline after 1 year of treatment. Analyses were done on an intention-to-treat basis. This trial is registered at ClinicalTrials.gov, number NCT00029848.
findings692 patients completed the 1 year follow-up; numbers in each group after 1 year were much the same. Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group (placebo: -1.4 kg [SD 3.6]; 5 mg/day: -2.3 kg [4.2], p=0.01 vs placebo; 20 mg/day: -5.3 kg [5.2], p<0.0001 vs placebo). Rimonabant was generally well tolerated. The incidence of adverse events that led to discontinuation was slightly greater in the 20 mg/day rimonabant group, mainly due to depressed mood disorders, nausea, and dizziness.
interpretationThese data indicate that 20 mg/day rimonabant, in combination with diet and exercise, can produce a clinically meaningful reduction in bodyweight and improve HbA1c and a number of cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes inadequately controlled by metformin or sulphonylureas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.